Literature DB >> 20840452

Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani.

Awanish Kumar1, Brijesh Sisodia, Pragya Misra, Shyam Sundar, Ajit Kumar Shasany, Anuradha Dube.   

Abstract

AIMS: This study aimed to identify differentially overexpressed membrane-enriched as well as cytosolic proteins in SAG sensitive and resistant clinical strains of L. donovani isolated from VL patients which are involved in the drug resistance mechanism.
METHODS: The proteins in the membrane-enriched as well as cytosolic fractions of drug-sensitive as well as drug-resistant clinical isolates were separated using two-dimensional gel electrophoresis and overexpressed identified protein spots of interest were excised and analysed using MALDI-TOF/TOF.
RESULTS: Six out of 12 overexpressed proteins were identified in the membrane-enriched fraction of the SAG resistant strain of L. donovani whereas 14 out of 18 spots were identified in the cytosolic fraction as compared with the SAG sensitive strain. The major proteins in the membrane-enriched fraction were ABC transporter, HSP-83, GPI protein transamidase, cysteine-leucine rich protein and 60S ribosomal protein L23a whereas in the cytosolic fraction proliferative cell nuclear antigen (PCNA), proteasome alpha 5 subunit, carboxypeptidase, HSP-70, enolase, fructose-1,6-bisphosphate aldolase, tubulin-beta chain have been identified. Most of these proteins have been reported as potential drug targets, except 60S ribosomal protein L23a and PCNA which have not been reported to date for their possible involvement in drug resistance against VL.
CONCLUSION: This study for the first time provided a cumulative proteomic analysis of proteins overexpressed in drug resistant clinical isolates of L. donovani indicating their possible role in antimony resistance of the parasite. Identified proteins provide a vast field to be exploited for novel treatment strategies against VL such as cloning and overexpression of these targets to produce recombinant therapeutic/prophylactic proteins.
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840452      PMCID: PMC2950996          DOI: 10.1111/j.1365-2125.2010.03716.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  40 in total

1.  SOSUI: classification and secondary structure prediction system for membrane proteins.

Authors:  T Hirokawa; S Boon-Chieng; S Mitaku
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Onchocerca volvulus glycolytic enzyme fructose-1,6-bisphosphate aldolase as a target for a protective immune response in humans.

Authors:  James S McCarthy; Moira Wieseman; Joe Tropea; David Kaslow; David Abraham; Sara Lustigman; Rocky Tuan; Ronald H Guderian; Thomas B Nutman
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  ABC transporters in Leishmania and their role in drug resistance.

Authors:  M Ouellette; D Légaré; A Haimeur; K Grondin; G Roy; C Brochu; B Papadopoulou
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

5.  Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.

Authors:  Susan Wyllie; Mark L Cunningham; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

6.  Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis.

Authors:  M P Molloy; B R Herbert; B J Walsh; M I Tyler; M Traini; J C Sanchez; D F Hochstrasser; K L Williams; A A Gooley
Journal:  Electrophoresis       Date:  1998-05       Impact factor: 3.535

7.  A subset of proteins found in culture supernatants of Candida albicans includes the abundant, immunodominant, glycolytic enzyme enolase.

Authors:  P Sundstrom; G R Aliaga
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

8.  Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.

Authors:  Esther Castanys-Muñoz; José María Pérez-Victoria; Francisco Gamarro; Santiago Castanys
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

9.  Evolution of tubulin gene arrays in Trypanosomatid parasites: genomic restructuring in Leishmania.

Authors:  Andrew P Jackson; Sue Vaughan; Keith Gull
Journal:  BMC Genomics       Date:  2006-10-18       Impact factor: 3.969

10.  Proteome analysis of the plasma membrane of Mycobacterium tuberculosis.

Authors:  Sudhir Sinha; Shalini Arora; K Kosalai; Abdelkader Namane; Alex S Pym; Stewart T Cole
Journal:  Comp Funct Genomics       Date:  2002
View more
  25 in total

1.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

2.  Molecular characterization and polyclonal antibody generation against core component CagX protein of Helicobacter pylori type IV secretion system.

Authors:  Gopal Jee Gopal; Awanish Kumar; Jagannath Pal; Gauranga Mukhopadhyay
Journal:  Bioengineered       Date:  2014-01-21       Impact factor: 3.269

3.  Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Authors:  Rati Tandon; Sharat Chandra; Rajendra Kumar Baharia; Sanchita Das; Pragya Misra; Awanish Kumar; Mohammad Imran Siddiqi; Shyam Sundar; Anuradha Dube
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 4.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

Review 5.  Heat Shock Proteins as the Druggable Targets in Leishmaniasis: Promises and Perils.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  Infect Immun       Date:  2021-01-19       Impact factor: 3.441

6.  Perspectives From Systems Biology to Improve Knowledge of Leishmania Drug Resistance.

Authors:  Elvira Cynthia Alves Horácio; Jéssica Hickson; Silvane Maria Fonseca Murta; Jeronimo Conceição Ruiz; Laila Alves Nahum
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

7.  Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis.

Authors:  Daniel R Abánades; Leonardo V Arruda; Elaine S Arruda; José Roberto A S Pinto; Mario S Palma; Dorlene Aquino; Arlene J Caldas; Manuel Soto; Aldina Barral; Manoel Barral-Netto
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

8.  Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovani.

Authors:  Sanchita Das; Priyanka Shah; Rati Tandon; Narendra Kumar Yadav; Amogh A Sahasrabuddhe; Shyam Sundar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  PLoS Negl Trop Dis       Date:  2015-08-21

Review 9.  Molecular Chaperones of Leishmania: Central Players in Many Stress-Related and -Unrelated Physiological Processes.

Authors:  Jose M Requena; Ana M Montalvo; Jorge Fraga
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

10.  Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression.

Authors:  Ippokratis Messaritakis; Vasiliki Christodoulou; Apostolos Mazeris; Eleni Koutala; Antonia Vlahou; Sevasti Papadogiorgaki; Maria Antoniou
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.